Journal
GENERAL HOSPITAL PSYCHIATRY
Volume 65, Issue -, Pages 21-27Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.genhosppsych.2020.03.006
Keywords
Benzodiazepine; Misuse; Chronic diseases; Practice guidelines
Categories
Funding
- University of Bordeaux, France
Ask authors/readers for more resources
Objective: To quantify benzodiazepine use non-compliant with guidelines in patients with psychiatric and non- psychiatric chronic diseases and assess the risk of non-recommended use associated with these diseases. Method: A cohort study was conducted in the French health insurance databases, including 254,488 new ben- zodiazepine users between 2007 and 2014. Psychiatric, cardiovascular, cancer, diabetes and in flammatory diseases were identi fied. Patients were followed for 2 years. Non-recommended use was de fined as excessive treatment duration, use of long half-life drugs in older patients and concomitant use of several benzodiazepines. Cox models identi fied the factors associated with non-recommended use. Results: Non-recommended use was frequent, ranging from 44.9% to 68.1%. It was independently associated with each chronic disease, with a slight increase in patients with chronic in flammatory disease (HR = 1.07; 95%CI 1.03-1.13) or diabetes (HR = 1.09; 1.06-1.12), a higher risk in those with chronic cardiovascular disease (HR = 1.34; 1.31-1.37) or cancer (HR = 1.30; 1.25-1.35) and the highest risk in those with psychiatric disease (HR = 2.04; 2.00-2.09). Conclusion: Patients with chronic disease have a high risk of benzodiazepine use leading to a higher exposure than recommended. Prescribers should be aware of the need to comply with the recommendations, especially in these patients who are the most frail and vulnerable to adverse events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available